Liposomal Bupivacaine Is Both Safe and Effective in Controlling Postoperative Pain After Spinal Surgery in Children: A Controlled Cohort Study.
Journal
Clinical spine surgery
ISSN: 2380-0194
Titre abrégé: Clin Spine Surg
Pays: United States
ID NLM: 101675083
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
24
4
2020
medline:
26
10
2021
entrez:
24
4
2020
Statut:
ppublish
Résumé
Retrospective comparative cohort study. To evaluate: (1) pain relief efficacy; (2) opioid consumption; (3) length of stay (LOS); (4) discharge disposition (DD); and (5) safety and adverse effects of liposomal bupivacaine (LB) in pediatric patients who underwent spinal deformity correction. LB is a long-acting, locally injectable anesthetic. Previous orthopedic studies investigating its use have been limited to adult patients. The use of LB as part of postoperative pain management in pediatric patients undergoing spine deformity correction surgery is yet to be evaluated. A total of 195 patients that received LB as part of their postoperative pain management regimen were compared with 128 patients who received standard pain management without LB. Pain intensity, opioid consumption, LOS, and DD were recorded. Potential LB-related complications were reported as frequencies and statistically compared for superiority. Noninferiority tests were performed using the Farrington-Manning score test. Multivariate tests based on generalized estimating equations were performed to determine the common and average treatment effects. Odds ratios (OR) with 95% confidence intervals (CI) were calculated. The LB cohort demonstrated lower pain scores [postoperative day 1 (POD 1)-median=2, interquartile range (IQR)=(0-5) vs. 5 (2.5-7); POD 2-3 (0-5) vs. 4 (3-6); P<0.001], lower overall opioid consumption (78.2 vs. 129 morphine milligram equivalents; P=0.0001) and consistently from POD 0 to 3 (mean differences; 7.47, 9.04, 17.2, and 17.3 morphine milligram equivalents, respectively; P<0.01), shorter LOS (median=3 d, IQR=3-4 vs. 4 d, IQR=4-6; P<0.001), and similar to-home DD (98% vs. 97%). Complications were similar among the cohorts in superiority and 10% noninferiority analyses. Patients in the LB cohort had lower odds for complications (odds ratio=0.77; 95% CI, 0.64-0.93; P=0.009 and 0.67; 95% CI, 0.50-0.90; P=0.008). This study demonstrated the safety and efficacy of LB when added to the current multimodal postoperative pain management regimens after pediatric spinal surgery. Level III.
Sections du résumé
STUDY DESIGN
Retrospective comparative cohort study.
OBJECTIVE
To evaluate: (1) pain relief efficacy; (2) opioid consumption; (3) length of stay (LOS); (4) discharge disposition (DD); and (5) safety and adverse effects of liposomal bupivacaine (LB) in pediatric patients who underwent spinal deformity correction.
SUMMARY OF BACKGROUND DATA
LB is a long-acting, locally injectable anesthetic. Previous orthopedic studies investigating its use have been limited to adult patients. The use of LB as part of postoperative pain management in pediatric patients undergoing spine deformity correction surgery is yet to be evaluated.
MATERIALS AND METHODS
A total of 195 patients that received LB as part of their postoperative pain management regimen were compared with 128 patients who received standard pain management without LB. Pain intensity, opioid consumption, LOS, and DD were recorded. Potential LB-related complications were reported as frequencies and statistically compared for superiority. Noninferiority tests were performed using the Farrington-Manning score test. Multivariate tests based on generalized estimating equations were performed to determine the common and average treatment effects. Odds ratios (OR) with 95% confidence intervals (CI) were calculated.
RESULTS
The LB cohort demonstrated lower pain scores [postoperative day 1 (POD 1)-median=2, interquartile range (IQR)=(0-5) vs. 5 (2.5-7); POD 2-3 (0-5) vs. 4 (3-6); P<0.001], lower overall opioid consumption (78.2 vs. 129 morphine milligram equivalents; P=0.0001) and consistently from POD 0 to 3 (mean differences; 7.47, 9.04, 17.2, and 17.3 morphine milligram equivalents, respectively; P<0.01), shorter LOS (median=3 d, IQR=3-4 vs. 4 d, IQR=4-6; P<0.001), and similar to-home DD (98% vs. 97%). Complications were similar among the cohorts in superiority and 10% noninferiority analyses. Patients in the LB cohort had lower odds for complications (odds ratio=0.77; 95% CI, 0.64-0.93; P=0.009 and 0.67; 95% CI, 0.50-0.90; P=0.008).
CONCLUSIONS
This study demonstrated the safety and efficacy of LB when added to the current multimodal postoperative pain management regimens after pediatric spinal surgery.
LEVEL OF EVIDENCE
Level III.
Identifiants
pubmed: 32324672
doi: 10.1097/BSD.0000000000000996
pii: 01933606-202012000-00021
doi:
Substances chimiques
Anesthetics, Local
0
Bupivacaine
Y8335394RO
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
E533-E538Références
Grant GJ, Barenholz Y, Bolotin EM, et al. A novel liposomal bupivacaine formulation to produce ultralong-acting analgesia. Anesthesiology. 2004;101:133–137.
Kalogera E, Bakkum-Gamez JN, Weaver AL, et al. Abdominal incision injection of liposomal bupivacaine and opioid use after laparotomy for gynecologic malignancies. Obstet Gynecol. 2016;128:1009–1017.
Saby A, Swaminathan K, Pangarkar S, et al. Alleviating thoracotomy pain with intercostal liposomal bupivacaine: a case report. PM R. 2016;8:1119–1122.
Cotta BH, Welliver C, Brahmamdam A, et al. Long-acting liposomal bupivacaine decreases inpatient narcotic requirements in men undergoing penile prosthesis implantation. Turk J Urol. 2016;42:230–234.
Cherian JJ, Barrington J, Elmallah RK, et al. Liposomal bupivacaine suspension, can reduce length of stay and improve discharge status of patients undergoing total hip arthroplasty. Surg Technol Int. 2015;27:235–239.
Chughtai M, Cherian JJ, Mistry JB, et al. Liposomal bupivacaine suspension can reduce lengths of stay and improve discharge status of patients undergoing total knee arthroplasty. J Knee Surg. 2016;29:224–227.
Puffer RC, Tou K, Winkel RE, et al. Liposomal bupivacaine incisional injection in single-level lumbar spine surgery. Spine J. 2016;16:1305–1308.
Khlopas A, Elmallah RK, Chughtai M, et al. The learning curve associated with the administration of intra-articular liposomal bupivacaine for total knee arthroplasty. A pilot study. Surg Technol Int. 2017;30:314–320.
Iorio R. The role of liposomal bupivacaine in value-based care. Am J Orthop (Belle Mead NJ). 2016;45:S13–S17.
Mistry JB, Chughtai M, Elmallah RK, et al. What influences how patients rate their hospital after total hip arthroplasty? J Arthroplasty. 2016;31:2422–2425.
Chughtai M, Jauregui JJ, Mistry JB, et al. What influences how patients rate their hospital after total knee arthroplasty? Surg Technol Int. 2016;28:261–265.
Baxter R, Bramlett K, Onel E, et al. Impact of local administration of liposome bupivacaine for postsurgical analgesia on wound healing: a review of data from ten prospective, controlled clinical studies. Clin Ther. 2013;35:312.e5–320.e5.
Mascha EJ, Imrey PB. Factors affecting power of tests for multiple binary outcomes. Stat Med. 2010;29:2890–2904.
VanWagner MJ, Krebs NM, Corser W, et al. Liposomal bupivacaine reduces opioid consumption and length of stay in patients undergoing primary total hip arthroplasty. HIP Int. 2019;29:276–281.
Talmo CT, Kent SE, Fredette AN, et al. Prospective randomized trial comparing femoral nerve block with intraoperative local anesthetic injection of liposomal bupivacaine in total knee arthroplasty. J Arthroplasty. 2018;33:3437–3478.
Tomov M, Tou K, Winkel R, et al. Does subcutaneous infiltration of liposomal bupivacaine following single-level transforaminal lumbar interbody fusion surgery improve immediate postoperative pain control? Asian Spine J. 2018;12:85–93.
Robbins J, Green CL, Parekh SG. Liposomal bupivacaine in forefoot surgery. Foot ankle Int. 2015;36:503–507.
Cloyd C, Moffett BS, Bernhardt MB, et al. Efficacy of liposomal bupivacaine in pediatric patients undergoing spine surgery. Paediatr Anaesth. 2018;28:982–986.
Grieff AN, Ghobrial GM, Jallo J. Use of liposomal bupivacaine in the postoperative management of posterior spinal decompression. J Neurosurg Spine. 2016;25:88–93.
Kim J, Burke SM, Kryzanski JT, et al. The role of liposomal bupivacaine in reduction of postoperative pain after transforaminal lumbar interbody fusion: a clinical study. World Neurosurg. 2016;91:460–467.
Schulz KF, Grimes DA. Sample size calculations in randomised trials: mandatory and mystical. Lancet. 2005;365:1348–1353.
Dorey FJ. In brief: Statistics in brief: Statistical power: What is it and when should it be used? Clin Orthop Relat Res. 2011;469:619–620.